| Recruitment status | Completed |
| Unique ID issued by UMIN | C000000178 |
| Receipt No. | R000000248 |
| Official scientific title of the study | Phase II Clinical Trial to Test Efficacy and Safety of Autologous Peripheral Stem Cell Transplantation for Multiple Myeloma (C-SHOT 0401) |
| Date of disclosure of the study information | 2005/09/12 |
| Last modified on | 2016/11/02 (Ver. 9) |
| Basic information | ||
| Official scientific title of the study | Phase II Clinical Trial to Test Efficacy and Safety of Autologous Peripheral Stem Cell Transplantation for Multiple Myeloma (C-SHOT 0401) | |
| Title of the study (Brief title) | Clinical Trial to Test Efficacy and Safety of Autologous Peripheral Stem Cell Transplantation for Multiple Myeloma (C-SHOT 0401) | |
| Region |
|
|
| Condition | ||
| Condition | multiple myeloma | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To test efficacy and safety of a series of treatment from induction chemotherapy to single peripheral autologous transplantation for patients with newly diagnosed multiple myeloma. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Response rate after 90 days from the transplantation |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Therapy is composed of the following three steps of therapy.
1. induction chemotherapy(3 courses of C-VAD regimen) 2. peripheral stem cell collection after high dose cyclophosphamide 3. autologous peripheral stem cell transplantation after high dose melphalan |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Multiple Myeloma(SWOG criteria).
2. Durie&Salomon Stage II or III. 3. No previous treatments 4. age >=16 and <= 65 5. PS 0-2(ECOG) 6. No clinically significant abnormalities in liver, heart and pulmonary functions 7. Written informed consent |
|||
| Key exclusion criteria | 1. Severe renal dysfunction
2. Severe cardiovascular dysfunction 3. Active infections 4. Active opportunistic infections 5. Active double cancers 6. Subjects who, in the opinion of the investigator, are not likely to participate in the study for any reason |
|||
| Target sample size | 60 | |||
| Research contact person | |
| Name of lead principal investigator | Isamu Sugiura |
| Organization | Toyohashi Municipal Hospital |
| Division name | Division of Hematology |
| Address | 50 Hakken-Nishi, Aotake-cho, Toyohashi #441-8570 |
| TEL | 0532-33-6111 |
| Public contact | |
| Name of contact person | Isamu Sugiura |
| Organization | Toyohashi Municipal Hospital |
| Division name | Division of Hematology |
| Address | 50 Hakken-Nishi, Aotake-cho, Toyohashi #441-8570 |
| TEL | 0532-33-6111 |
| Homepage URL | http://www.c-shot.or.jp/ |
| isugiura-sgr@umin.ac.jp | |
| Sponsor | |
| Institute | Center for Supporting Hematology-Oncology Trials (C-SHOT) |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Nagoya BMT group |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | JAPAN |
| Other related organizations | |
| Co-sponsor | Nagoya Muliple Myeloma Collaborated Group |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | http://www.c-shot.or.jp/ |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000248 |